Our innovative R+D Diagnostics program focuses on the development of novel molecular diagnostic tools specifically designed to detect biomarkers in clinical use. Using standard techniques, we focus on development of new assays to detect validated biomarkers such as EGFR, ALK, ROS, BRCA1, BRAF and others.
‘Liquid Biopsy’ Program
We are leaders in the field of non-invasive diagnostic tests using alternative biosources such as cerebrospinal fluid or serum, plasma and platelets from blood samples. In certain types of cancer such as lung cancer, insufficient tumor tissue obtained by traditional biopsy can mean it is not possible to perform vital diagnostic tests. Our blood tests not only overcome this difficulty, but also permit real time monitoring of the disease and early detection of resistance. Our assays have the required sensitivity and specificity for immediate incorporation into clinical practice.
As an example of our capabilities in this field, we have developed highly sensitive and specific techniques with clinical applications for the detection of genetic alterations in blood of lung cancer patients.